Skip to main content

Myositis

Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more! #ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 09, 2021
Thanks Dr David Fiorentino for his talk on CA and myositis! ⬆️risk: - DM - >45-50yo - males - TIF1-gamma Ab (4.7RR of CA) - NXP2 - low CK - dysphagia ⬇️ risk: - synthetase Ab - raynaud - ILD - inflamm arth 🚨TIF1-gamma🚨 - ovarian CA (older, IgG2) #ACR21 #ACRAmbassador

Vaneet K Sandhu, MD (she/her/hers) @vksandhumd( View Tweet )

Nov 09, 2021
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation Now there hope might be on the horizon Exciting to see the science & a feasible target #ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
Nov 09, 2021
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21 ⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis. ➡️Amyopathic (MDA5) dermatomyositis @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021
Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality ~0.4% frequency, mortality 22% when myositis alone ~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42% #ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 07, 2021
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ
Nov 07, 2021
@KatGilekMD @RichardPAConway @RheumNow @drhectorchinoy EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.

Rohit Aggarwal @docrota( View Tweet )

Nov 07, 2021
@NU_Rheum_MSK_US @RichardPAConway @drhectorchinoy @RheumNow Muscle ultrasound can be very useful but it is not ready for prime time currently to be used to do muscle biopsies. Perhaps in few years once we know how to target the muscle for biopsy.

Rohit Aggarwal @docrota( View Tweet )

Nov 07, 2021
Clinical (Peds Rheum) Pearl at #ACR21 by Dr. John Stone: ⭐️Dilated capillaries at the eyelid margin is the last cutaneous sign to resolve in inflammatory myositis! ⭐️Do not stop treatment until this sign is gone! #ACRBest @RheumNow https://t.co/5H3Q9mTN9x
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 07, 2021
#ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 07, 2021
Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
TheDaoIndex @KDAO2011( View Tweet )
Nov 06, 2021
KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
Nov 06, 2021
In case you missed it…a popular read. Clinical Associations with Myositis Antibodies Read the full article on #RheumNowhttps://t.co/tzPU1scc8x https://t.co/pmmtmIuz31
Dr. John Cush @RheumNow( View Tweet )
Oct 16, 2021
Clinical Associations with Myositis Antibodies Read the full post on #RheumNowhttps://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Dr. John Cush @RheumNow( View Tweet )
Oct 11, 2021
antisynthetase,myositis,nail,erythema

Clinical Associations with Myositis Antibodies

Oct 07, 2021

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article
ICYMI: JAK inhibitors as potential treatment for Juvenile Dermatomyositis: nice review of the biology of JAKi effects and the reports of JAKi success in adults and kids with IIM https://t.co/k3qunsCdBN https://t.co/nyqMo6vh88
Dr. John Cush @RheumNow( View Tweet )
Oct 03, 2021
RheumNow Podcast square

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Oct 01, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com




  1. A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
arm,muscle,weak

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in

Read Article
infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today
Sep 14, 2021

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Dr. John Cush @RheumNow( View Tweet )

Sep 10, 2021
RheumNow Podcast square

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
Differential Dx of immune-mediated necrotizing myopathies (IMNM) - HMGCR & Signal recognition particle Abs; checkpoint inhibitors, anti-Mi2 dermatomyositis, antisynthetase syndr. antimitochondrial Abs, GVHD, SARS-CoV-2 infection https://t.co/hhizx5gAet

Dr. John Cush @RheumNow( View Tweet )

Sep 10, 2021
Popular on RheumNowhttps://t.co/BZsl8a6ArWThe U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx
Dr. John Cush @RheumNow( View Tweet )
Aug 16, 2021
×